SciELO - Scientific Electronic Library Online

 
vol.15 issue1Stakeholders' perceptions of the delivery and quality of sexually transmitted infection treatment by private practitioners in Windhoek, NamibiaReasons for students' poor clinical competencies in the Primary Health Care: Clinical nursing, diagnosis treatment and care programme author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Health SA Gesondheid (Online)

On-line version ISSN 1025-9848

Health SA Gesondheid (Online) vol.15 n.1 Cape Town  2010

 

ORIGINAL RESEARCH

 

Further potential savings attributable to maximum generic substitution of antidepressants in South Africa: A retrospective analysis of medical claims

 

 

Elmarie van der Westhuizen; Johanita R. Burger; Martie S. Lubbe; Jan H.P. Serfontein

School of Pharmacy, North-West University, Potchefstroom campus, South Africa

Correspondence

 

 


ABSTRACT

The main objective of the study was to calculate potential cost savings that could have been generated by maximum generic substitution of antidepressants within the private health care sector of South Africa from 2004 to 2006. Data on computerised medicine claims of patients receiving one or more antidepressants during three consecutive years (i.e. 2004, 2005 and 2006) were elicited from a South African pharmaceutical benefit management company. The total study population consisted of 292 071 items (N = 5 982 869) on 273 673 prescriptions (N = 5 213 765) at a total cost of R56 183 697.91 (N = R1 346 210 929.00). A quantitative, retrospective drug utilisation review was conducted, and data were analysed using the Statistical Analysis System® programme. Potential cost savings were computed for criteria-eligible substances in the study population. Generic medicine constituted 58.7% (N = 292 071) of all antidepressants claimed, at a total cost of 28.2% (N = R1 346 210 929.00) of all incurred costs. With total substitution of the average price of all criteria-eligible innovators, a potential saving of 9.3% (N = R56 183 697.91) of the actual antidepressant cost over the study period was calculated. In developing countries with limited health care resources, generic medicines can be cost-saving treatment alternatives.

Keywords: cost savings; drug utilisation review; generic equivalents; innovators; Statistical Analysis System® program


OPSOMMING

Die hoofmikpunt van hierdie studie was om die potensiële kostebesparing te bereken wat deur maksimale generiese vervanging van antidepressante in die Suid-Afrikaanse private gesondheidsorgsektor tussen 2004 en 2006 teweeggebring sou kon word. Data oor gerekenariseerde eise vir medisyne van pasiënte wat een of meer antidepressante gedurende die studietydperk ontvang het (d.i. 2004, 2005 en 2006) is van 'n Suid-Afrikaanse maatskappy wat farmaseutiese voordele bestuur, verkry. Die totale studiepopulasie het bestaan uit 292 071 items (N = 5 982 869) van 273 673 voorskrifte (N = 5 213 765) teen 'n totale koste van R56 183 697.91 (N = R1 346 210 929.00). 'n Kwantitatiewe, retrospektiewe medisyneverbruiksontleding is gedoen en data is geanaliseer deur van die Statistical Analysis System®-pakket gebruik te maak. Potensiële kostebesparings is vir middels in die studiepopulasie wat aan die kriteria voldoen het, bereken. Generiese produkte het 58.7% (N = 292 071) van alle produkte wat voorgeskryf is, uitgemaak, teen 'n totale koste van 28.2% (N = R1 346 210 929.00). Indien die gemiddelde prys van alle middels wat aan die kriteria vir vervanging voldoen het, met die prys vir generiese middels vervang word, is 'n potensiële besparing van 9.3% (N = R56 183 697.91) van die werklike koste vir antidepressante gedurende die studietydperk moontlik. Generiese middels kan in ontwikkelende lande met beperkte gesondheidsorg-hulpbronne kostebesparende alternatiewe wees.


 

 

“Full text available only in PDF format”

 

 

REFERENCES

Andersson, K., Sonesson, C., Petzold, M., Carlsten, A. & Lönnroth, K., 2005, 'What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden', Pharmacoepidemiology and Drug Safety 14(5), 341-348.         [ Links ]

Banahan, B.F. & Kolassa, E.M., 1997, 'A physician survey on generic drugs and substitution of critical dose medications', Archives of Internal Medicine 157(18), 2080-2088.         [ Links ]

Bester, M., Brews, M. & Hammann, E., 2006, Mediscor medicines review-2005, viewed 2 September 2006, from http://www.mediscor.net        [ Links ]

Bester, M. & Hammann, E., 2007, Mediscor medicines review-2006, viewed 13 August 2007, from http://www.mediscor.net        [ Links ]

Bester, M. & Hammann, E., 2008, Mediscor medicines review-2007, viewed 25 August 2009, from http://www.mediscor.net        [ Links ]

Blecher, M. & Harrison, S., 2006, 'Health care financing', in P. Ijumba & A. Padarath (eds.), South African health review-2006, pp. 31-64, Health Systems Trust, Durban.         [ Links ]

Bloem, J., 2009, A retrospective analysis of the usage patterns of hipolipidaemic drugs: A pharmacoeconomic approach, M Pharm Dissertation, Dept. of Pharmacy Practice, North-West University.         [ Links ]

Boersma, C., Klok, R.M., Bos, J.M., Naunton, M., Van den Berg, P.B., De Jong-van den Berg, L.T.W. et al., 2005, 'Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: A study conducted for The Netherlands', Applied Health Economics and Health Policy 4(3), 191-196.         [ Links ]

Boyce, D. & Bartlett, G., 1990, 'The maximum medical aid price programme: A review of the concept and of its ability to reduce expenditure on medicine', South African Pharmaceutical Journal 78, 147-151.         [ Links ]

Cohen, J., 1988, 'Statistical power analysis for the behavioural sciences', Erlbaum, Hillsdale, New Jersey.         [ Links ]

Department of Health, 1996, National drug policy for South Africa, Government Printer, Pretoria.         [ Links ]

Department of Health, 2004, Regulations relating to a transparent pricing system for medicines and scheduled substances, Government Gazette No.29443, 01 December 2006.         [ Links ]

Department of Health, 2007, Macro-analysis of the current situation in private health sector, viewed 22 October 2008, from http://www.doh.gov.za/docs/presentation/indaba/macro-analysis.pdf        [ Links ]

Deroukakis, M., 2007, 'Mandatory substitution successful', South African Pharmaceutical Journal 97, 63-64.         [ Links ]

Frank, R.G., 2007, 'The ongoing regulation of generic drugs', The New England Journal of Medicine 357(20), 1993-1996.         [ Links ]

Frank, R.G. & Salkever, D.S., 1997, 'Generic entry and the pricing of pharmaceuticals', Journal of Economics & Management Strategy 6(1), 75-90.         [ Links ]

Gaither, C.A., Kirking, D.M., Ascione, F.J. & Welage, L.S., 2001, 'Consumers' views on generic medications', Journal of the American Pharmaceutical Association 41(5), 729-736.         [ Links ]

Global Insight Inc., 2007, Generic substitution saves Finland US$54.8 mil. in 2007, viewed 16 May 2008, from http://www.globalinsight.com/SDA/SDADetail11882.htm        [ Links ]

Haas, J.S., Phillips, K.A., Gerstenberger, E.P. & Seger, A.C., 2005, 'Potential savings from substituting generic drugs for brand-name drugs: Medical expenditure panel survey, 1997-2000', Annals of Internal Medicine 142(11), 891-897.         [ Links ]

Karim, S.S.A., Pillai, G., Ziqubu Page, T.T., Cassimjee, M.H. & Morar, M.S., 1996, 'Potential savings from prescribing and generic substitution in South Africa', Health Policy and Planning 11(2), 198-205.         [ Links ]

Leon, N. & Mabope, R., 2005, 'The private health sector', in P. Ijumba & P. Barron (eds.), South African health review-2005, pp. 32-43, Health Systems Trust,Durban.         [ Links ].

Levinson, D.R., 2006, Generic drug utilization in state Medicaid programs, viewed 15 June 2008, from http://www.oig.hhs.gov/oei/reports/oei-05-05-00360.pdf        [ Links ]

Masobe, T.P., 2008, 'Executive summary', in Office of the Registrar of Medical Schemes, Evaluation of medical schemes' cost increases: Findings and recommendations, pp. 9-14, Council for Medical Schemes, Pretoria.         [ Links ]

McIntyre, D. & Thiede, M., 2007, 'Health care financing and expenditure', in S. Harrison., R. Bhana & A. Ntuli (eds.), South African health review-2007, pp. 35-46, Health Systems Trust, Durban.         [ Links ]

McLeod, H. & Ramjee, S., 2007, 'Medical schemes', in S. Harrison., R. Bhana & A. Ntuli (eds.), South African health review-2007, pp. 47-70, Health Systems Trust, Durban.         [ Links ]

McManus, P., Birkett, D.J., Dudley, J. & Stevens, A., 2001, 'Impact of the minimum pricing policy and introduction of brand (generic) substitution into pharmaceutical benefits scheme in Australia', Pharmacoepidemiology and Drug Safety 10(4), 295-300.         [ Links ]

Medicines Control Council, 2003, Generic substitution, Department of Health, South Africa.         [ Links ]

Morgan, S.G., Agnew, J.D. & Barer, M.L., 2004, 'Seniors' prescription drug cost inflation and cost containment: Evidence from British Columbia', Health Policy 68(3), 299-307.         [ Links ]

Mott, D.A. & Cline, R.R., 2002, 'Exploring generic use behavior: The role of prescribers and pharmacists in the opportunity for generic use and generic substitution', Medical Care 40(8), 662-674.         [ Links ]

Pick, W., 2008, 'Foreword', in Office of the Registrar of Medical Schemes, Evaluation of medical schemes' cost increases: Findings and recommendations, pp. 7-8, Council for Medical Schemes, Pretoria.         [ Links ]

Quick, J.D., Hogerzeil, H.V., Velasquez, G. & Rägo, L., 2002, 'Twenty-five years of essential medicines', Bulletin of the World Health Organization 80(11), 913-914.         [ Links ]

SAS version 9.1, 2005, computer software, The SAS Institute Inc., Cary, New York.         [ Links ]

Simoens, S., De Bruyn, K., Bogaert, M. & Laekeman, G., 2005, 'Pharmaceutical policy regarding generic drugs in Belgium', Pharmacoeconomics 23(8), 755-766.         [ Links ]

Snyman, J.R. (ed.), 2006, Monthly index of medical specialities, MIMS, Pretoria.         [ Links ]

South Africa Government, 1997, Medicines and Related Substance Control Amendment Act, Government Printer, Pretoria.         [ Links ]

Steyn, R., 2005, The usage of antidiabetic drugs: A managed care approach, M Pharm Dissertation, Department of Pharmacy Practice, North-West University.         [ Links ]

Taylor, B., 2007, 'Rationing of medicines and health care technology', in S. Harrison., R. Bhana & A. Ntuli (eds.), South African health review-2007, pp. 123-138, Health Systems Trust, Durban.         [ Links ]

Tilson, L., McGowan, B., Ryan, M. & Barry, M., 2003, 'Generic drug utilisation on the General Medical Services (GMS) Scheme in 2001', Irish Medical Journal 96(6), 176-179.         [ Links ]

Ubeda, A., Cardo, E., Sellés, N., Broseta, R., Trillo, J.L. & Fernández-limós, F., 2007, 'Antidepressant utilization in primary care in a Spanish region: Impact of generic and reference-based pricing policy (2000-2004)', Social Psychiatry and Psychiatric Epidemiology 42(3), 181-188.         [ Links ]

Van der Westhuizen, E., 2007, Overview of antidepressants usage and cost 2004 until 2006, M Pharm Dissertation, Dept. of Pharmacy Practice, North-West University.         [ Links ]

World Bank., 2009, South Africa - country brief, viewed 13 August 2009, from http://www.worldbank.org        [ Links ]

World Health Organization, 2008, World health statistics-2008, World Health Organization, Geneva.         [ Links ]

 

 

Correspondence:
Johanita Burger
School of Pharmacy, North-West University
Private Bag X6001
Potchefstroom 2520
South Africa
email: johanita.burger@nwu.ac.za

Received: 11 Nov. 2009
Accepted: 04 June 2010
Published: 24 Nov. 2010

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License